Diligence memo · auto-generated · as of July 2, 2026
SiNON Therapeutics
SiNON Therapeutics looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
SiNON Therapeutics operates in Biotechnology, based in DURHAM.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
SiNON Therapeutics has raised $169K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $169K on 2020-10-01.
Most recent recorded round closed around 2020-10-01.
Valuation (modeled)modeled
Provath models SiNON Therapeutics at approximately $8.0M (range $90K–$84M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.51× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 5.7 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 3% of Biotechnology peers (4293 compared).
Modeled value ranks above 15% of those peers.
Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.